SCHEMBL233034

SCHEMBL233034

Cc1ccc(Br)cc1OC(C)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.56
TSHR P16473 1/20 0.54
HTR2A P28223 1/20 0.54
HTR2C P28335 1/20 0.54
HTR2B P41595 1/20 0.54
KMT2A Q03164 2/20 0.47
HPGD P15428 4/20 0.41
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 3/20 0.41
HSD17B10 Q99714 2/20 0.41
LMNA P02545 1/20 0.41
ATM Q13315 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CYP1A2 P05177 1/20 0.40
GAA P10253 1/20 0.40
CYP2C9 P11712 1/20 0.40
PKM P14618 1/20 0.40
CYP2C19 P33261 1/20 0.40
LDHA P00338 1/20 0.40
PTGDR2 Q9Y5Y4 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18330954 0.87 TSHR (0.67) TDP1TSHRHTR2AHTR2CHTR2B
SCHEMBL23368020 0.87 TSHR (0.67) TDP1TSHRHTR2AHTR2CHTR2B
SCHEMBL11297323 0.85 KMT2A (0.49) TDP1TSHRHTR2AHTR2CHTR2B
SCHEMBL7277166 0.83 TDP1 (0.59) TDP1TSHRHTR2AHTR2CHTR2B
SCHEMBL25329420 0.82 TSHR (0.49) TDP1TSHRHTR2AHTR2CHTR2B
SCHEMBL20516340 0.82 TSHR (0.53) TDP1TSHRHTR2AHTR2CHTR2B
SCHEMBL20516343 0.82 TSHR (0.53) TDP1TSHRHTR2AHTR2CHTR2B
SCHEMBL23924764 0.82 KMT2A (0.63) TDP1TSHRHTR2AHTR2CHTR2B
SCHEMBL25329418 0.82 TSHR (0.49) TDP1TSHRHTR2AHTR2CHTR2B
SCHEMBL21057246 0.81 SMN1; SMN2 (0.58) TDP1TSHRHTR2AHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590931-B1 (2-ARYLOXY-ACETYLAMINO)-PHENYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS MEDICAMENT SANOFI SA (FR) 2014-04-30 EP disclosed
US-8648038-B2 (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments SANOFI (FR) 2014-02-11 US disclosed
EP-2590931-A1 (2-ARYLOXY-ACETYLAMINO)-PHENYL-PROPIONIC ACID DERIVATIVES, METHOD FOR PRODUCING SAME AND USE THEREOF AS PHARMACEUTICALS SANOFI (FR) 2013-05-15 EP disclosed
WO-2012004269-A1 (2-ARYLOXY-ACETYLAMINO)-PHENYL-PROPIONIC ACID DERIVATIVES, METHOD FOR PRODUCING SAME AND USE THEREOF AS PHARMACEUTICALS SANOFI (FR) 2012-01-12 WO disclosed
US-20120004167-A1 (2-ARYLOXYACETYLAMINO) PHENYLPROPIONIC ACID DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF AS MEDICAMENTS SANOFI (FR) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004167-A1 (2-ARYLOXYACETYLAMINO) PHENYLPROPIONIC ACID DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF AS MEDICAMENTS GPR119, DPP9, DPP7 TDP1 3790/4885TSHR 377/4885HTR2A 3080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.